116 results about "Chronic renal disease" patented technology

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention relates to nutritional compositions and methods of using these compositions for the treatment of renal disease. More particularly, the invention discloses compositions of vitamins, minerals, amino acids, and/or proteins in amounts that can be used to supplement the nutritional deficiencies observed in patients afflicted with renal disease, renal insufficiency, or end-stage renal disease. The compositions of the invention can also be used as nutritional supplements for patients undergoing dialysis therapy or for patients on a restricted diet. In addition, the compositions can be used in combination or alone as a method of treating or managing a subject in the various stages of chronic renal disease, or throughout disease progression.

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin Din a patient by administering 25-hydroxyvitamin D₃ with or without 25-hydroxyvitamin D₂ and, as necessary, 1,25-dihydroxyvitamin D₂ as a Vitamin D hormone replacement therapy.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention discloses a composition for patients with chronic renal disease and preparing method thereof, and belongs to the technical field of medical food. The composition is prepared from, 33.4-58.6 g/l of protein, 62.5-123 g/l of fat, 204-305 g/l of carbohydrates, 5.0-20 g/l of dietary fiber, 0.14-0.68 g/l of phosphorus, 0.2-1.68 g/l of sodium, 0.2-2.00 g/l of potassium, 0.3-1.33 g/l of calcium, 0.04-0.30 g/l of magnesium, 1.0-2.25 mg RE/L of vitamin A, 4.6-8.6 mg RE/L of vitamin B complex, microelement, other vitamins, and water. The invention matches scientifically, and has high heat,low phosphorus ,sodium and potassium.The content of vitamin A is low while the content of vitamin B is high, conforming to the principle of nutrition support. The composition is easy to digest and is the main nutrient source of patients with chronic renal disease.

The invention discloses a naphthyl sulfamide amino acid derivative, a preparation method and medical application thereof. A naphthyl sulfamide amino acid derivative R3 substituent group represents a substituent group with an amino acid structure; the amino acid structure refers that the substituent group at least contains one carboxyl and one secondary amine or tertiary amine, and the substituentgroup is connected onto a mother nucleus through the secondary amine or the tertiary amine. The naphthyl sulfamide amino acid derivative provided by the invention can interfere with Keap1-Nrf2 combination and activate Nrf2, so that inflammatory injury is reduced, an inflammation microenvironment is improved, and the naphthyl sulfamide amino acid derivative has potential anti-inflammatory activity.The technician in the field knows that an Nrf2 activating agent can be used for inhibiting inflammatory reaction of diseases, so that the compound provided by the invention can be used for preparingan anti-inflammatory drug for treating diseases associated with inflammation, including chronic obstructive pulmonary diseases, Alzheimer diseases, Parkinson, atherosclerosis, chronic renal diseases,diabetes, intestinal inflammation, rheumatoid arthritis and the like.

The invention provides a nutrient solution suitable for chronic renal disease patients free from dialysis and a preparing method. The nutrient solution comprises 1-30% of maltodextrin, 1-5% of protein, 1-5% of fructose, 1-5% of saccharose, 1-7% of isomaltulose, 1-10% of mixed plant oil, 1-7% of medium chain triglyceride, 1-2% of cellulose, 1-2% of fructooligosaccharide, 0.01-1% of mineral substance, 0.01-1% of decavitamin, 0.01-2% of fish oil, 0.01-1% of emulsifying agent, 0.001-0.01% of L-carnitine and L-taurine, and the balance water. The nutrient solution is prepared through a conventional method. The nutrient solution provides suitable nutrition for the chronic renal disease patients free from dialysis, and kidney burdens of the patients are reduced while energy is replenished.

A human having an erythropoietin resistant condition is treated by the administration of an iron chelator. The human can have end-stage renal disease, chronic renal disease, cancer or anemia. Administration of the iron chelator can essentially halt or diminish an erythropoietin resistant condition in a human.

Disclosed is a nutrient solution for treating chronic kidney diseases and its preparing process, wherein each 500ml of the nutrient solution contains carbohydrate compound 55-65g, saturated fatty acid 10-12g, mono-saturated fatty acids 20-24g, protein 6-10g, zinc 5-10mg, ferrum 10-15mg, calcium 0.2-0.5g, cellulose 3-3.5g, complex vitamin B 10-30mg, active vitamin D 0.5-0.8ug, folic acid 1-2mg, vitamin C 50-100mg, pantothenic acid 3-5mg, yeast 10-15g, and probiotic 210-250mg.

The invention relates to a traditional Chinese medicine composition for treating tuberculosis, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw material medicine: hoantchy root, rhizome polygonati, lily, dwarf lilyturf turber, radix stemonae, bletilla, peach kernel, salvia miltiorrhiza, donkey-hide gelatin, wild buckwheat root, bulbus fritilariae, trichosanthes bark, and radix glehniae. The medicine is generally suitable for tuberculosis patients, particularly suitable for patients suffering from combined chronic diseases such as tubercular meningitis, diabetes, chronic liver disease, chronic renal disease, and the like, fever, night sweat, and physical weakness.

The invention relates to the fields of application of health, biotechnology and nutrition, the aim of the invention being to provide a gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease, the characteristics and components thereof reducing the concentration of uremic toxins, improving the renal function of the patient with an increase in urea, creatinine, uric acid, p-cresols or indoles in the blood. The gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease is easier to administrate orally as it does not require the consumption of liquids for the administration thereof, reducing liquid retention. Another advantage of the present invention is the fact that it refers to live and active bacteria. The present invention is also used a primary source of food with known prebiotic effects, an element which is not considered in other inventions; it is not in a pharmaceutical form. The probiotic bacteria are found “live and active” and in “synergic action” with the prebiotic fibres of plant origin such as “blue agave fructans (blue agave inulin)”.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 6-40 parts of rheum officinale, 10-95 parts of astragalus and 5-65 parts of salvia miltiorrhiza by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum creatinine and urea nitrogen and other indexes of rats subjected to hypertensive nephropathy, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; and pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure.

The invention discloses a traditional Chinese medicine compound combination with a function of curing chronic kidney diseases. The traditional Chinese medicine compound combination is prepared by 20-60 parts of astragali radix, 15-45 parts of eucommia ulmoides, 10-30 parts of glossy privet fruit, 10-30 parts of cherokee rose fruit, 30-90 parts of caulis sinomenii, 30-90 parts of herba pyrrosiae, 15-45 parts of radix ranunculi ternati, 20-60 parts of rhizoma dioscoreae nipponicae, 15-45 parts of stiff silkworms and 5-15 parts of scorpion. The invention further discloses a preparation method of the traditional Chinese medicine compound combination and an application of the traditional Chinese medicine compound combination in curing the curing chronic kidney diseases. The traditional Chinese medicine compound combination is obtained through long-time clinical application and screening under the guidance of the traditional Chinese medicine theory according to the pathogenesis of the chronic kidney diseases. Clinical test results show that the traditional Chinese medicine compound combination can remarkably reduce proteinuria, protect the kidney function and control and stabilize the illness condition of a patient suffering from chronic nephritis, the effective rate is up to 91.7%, no remarkable adverse reaction occurs in the test process, the application is safe, and the traditional Chinese medicine compound combination is hopeful to be developed into a new drug for curing proteinuria of chronic nephritis.

The invention discloses a Chinese materia medica preparation for curing a chronic kidney disease and a preparation method of the Chinese materia medica preparation. The Chinese materia medica preparation comprises astragalus root, pilose asiabell root, largehead atractylodes rhizome, indian buead, common yam rhizome, polygonum multiflorum, dodder, coix seed and salvia miltiorrhiza. The preparation method includes crushing raw ingredients, adding water to soak, boiling, decocting the raw ingredients, filtering, adding water into filter residues, repeating decoction, filtering, mixing two filter liquors, and obtaining the Chinese materia medica preparation. On the basis of the research of the field, the Chinese materia medica preparation is integrated with essence of the industry and is formed after being subjected to repeated demonstrations and optimizations. The Chinese materia medica preparation includes nine drugs such as the astragalus root, the pilose asiabell root, the dodder and the like, has a function of reinforcing spleen and kidney, has an obvious curative effect on the chronic kidney disease, particularly is good in effects of slowing down the decreasing of epidermal growth factor receptor (EGFR) of patients with chronic kidney disease stage 4 and the advancement of the chronic kidney disease, and is superior to an effective drug angiotensin-converting enzyme inhibitor (ACEI) internationally used.

The invention provides a traditional Chinese medicine composition for treating chronic kidney diseases and chronic renal failure. The traditional Chinese medicine composition is prepared from radix et rhizoma rhei preparata, Chinese peashrub roots, herba centellae, rhizoma curcumae, radix salviae miltiorrhizae, rhizoma smilacis glabrae, flos carthami, rhizoma polygoni cuspidati, herba pyrolae, lucid ganoderma, radix astragali and fructus aurantii. The radix et rhizoma rhei preparata has the effects of promoting blood circulation, detoxifying and eliminating turbidity, the Chinese peashrub roots has the effects of dispelling wind, detoxifying and reducring urinary protein, the herba centellae has the effects of dispelling wind, detoxifying and reducing creatinine, the rhizoma curcumae has the effects of breaking blood, promoting qi and resisting fibrosis, the radix salviae miltiorrhizae and the flos carthami have the effects of promoting blood circulation and removing blood stasis, the rhizoma smilacis glabrae has the effects of clearing heat, detoxifying and drying dampness, the rhizoma polygoni cuspidati has the effects of dispelling wind, detoxifying and reducing uric acid, the herba pyrolae has the effects of tonifying kidney and clearing away dieresis, the lucid ganoderma and the radix astragali have the effects of invigorating qi and strengthening health, and the fructus aurantii has the effects of soothing liver and regulating qi. The traditional Chinese medicine composition can effectively reduce proteinuria and hematuria of patients with chronic kidney diseases, relieve renal function progression of chronic renal failure, reduce serum creatinine, improve clinical symptoms of patients with chronic kidney diseases, especially chronic renal failure, and protect renal functions.

The present invention relates to a method for diagnosis of a chronic kidney disease in a subject by detecting the expression level of a sodium-glucose linked transporter 2 (SGLT2) protein in urine samples. A method for monitoring progression of a chronic kidney disease in a patient is also provided.

The invention provides methods for treating or preventing bone degenerative disorders. The disorders treated or prevented include, for example, osteopenia, osteomalacia, osteoporosis, osteomyeloma, osteodystrophy, Paget's disease, osteogenesis imprerfecta, and bone degenerative disorders associated with chronic renal disease, hyperparathyroidism, high levels of endogenous thyrotropin, and long-term use of corticosteroids. The disclosed therapeutic methods include administering to a mammal a TSHR agonist in an amount effective to: (1) treat or prevent a bone degenerative disorder; (2) slow bone deterioration; (3) restore lost bone; (4) stimulate new bone formation; and/or (5) maintain bone mass and/or bone quality. TSHR agonists such as thyrotropin and its modified forms are provided along with other compounds, such as anti-resorptive agent and bone metabolic agents.

The invention discloses a sharpleaf galangal fruit extract capable of treating chronic kidney diseases. The extract is prepared by the following steps: grinding sharpleaf galangal fruits to remove the shells, adding a certain amount of ethanol, carrying out reflux extraction, collecting the extract, making the extract go through macroporous resin, eluting the macroporous resin by low-concentration ethanol to remove the impurities, then eluting the macroporous resin by high-concentration ethanol, condensing to obtain extract, separating the extract in a silica gel column, and carrying out crystallization so as to obtain the sharpleaf galangal fruit extract. According to the pathogenesis of chronic kidney diseases and on the basis of traditional Chinese medicine theory, the inventor researches the chemical components and the clinical curative effect of sharpleaf galangal fruit. The results of a great number of experiments show that the prepared sharpleaf galangal fruit extract (nootkatone) can prominently reduce proteinuria, can also obviously reduce the levels of serum creatinine and urea nitrogen, has a good kidney protective effect, and can be used to prevent and treat chronic kidney diseases.

The invention discloses a strain namely bifidobacterium bifidum CCTCC No.M2017063. The strain has a strong performance on assisting the treatment of renal diseases, is separated from feces of healthyinfants, is a gram positive polymorphic bacillus, has a strong performance on degrading serum creatinine and urea nitrogen of mice, can be made into a microbial inoculant, can be used as a ferment oradditive, and can improve the health of patients of renal diseases.

The invention discloses a traditional Chinese medicine preparation for treating qi-yin deficiency syndrome of a chronic kidney disease. The traditional Chinese medicine preparation comprises the following raw materials in parts by weight: 8-12 parts of dried radix rehmanniae, 8-12 parts of poria cocos, 8-12 parts of Chinese yam, 6-10 parts of dogwood, 8-12 parts of astragalus membranaceus, 8-12 parts of codonopsis pilosula, 8-12 parts of semen coicis, 8-12 parts of corn stigma, 12-18 parts of lalang grass rhizome, 8-12 parts of madder, 8-12 parts of herba cepbalanoplosis segeti, 8-12 parts of fructus rosae laevigatae and 8-12 parts of semen euryales. The preparation method comprises the following steps: during preparation, firstly, decocting various raw materials for three times according to the required ratio; mixing decoctions of three times; filtering and concentrating into thick paste of which the relative density is 1.2-1.3; and adding auxiliary materials, pelletizing and drying to prepare the traditional Chinese medicine preparation. The traditional Chinese medicine preparation has the efficacies of tonifying the kidneys and spleen, securing essence and clearing dampness, and tonifying qi and nourishing yin, and has a significant curative effect on hematuresis, proteinuria and abnormal renal function caused by chronic kidney diseases when the kidney function is protected.

The invention relates to a drug for treating chronic kidney disease proteinuria, which is a capsules prepared as follows: the materials are astragalus, Oriental Waterplantain Rhizome, Chinese Magnolivine Fruit, fried foxnut and node of lotus rhizome, which are added to water to be decocted, and the decoction solution is concentrated and dried. The drug has the advantages of kidney invigorating, diuresis inducing and stranguria treating, blood activating and stasis removing, swelling reducing and pain alleviating, heat-clearing and detoxifying, body fluid regenerating and thirst quenching, darrhea relieving, cough relieving and bleeding stopping, which has the function of body immunity regulation and reinforcing, and is suitable for the patient with chronic kidney disease and chronic renal failure proteinuria; the drug can effectively reduce proteinuria, increase plasma albumin, reduce the pathological changes of kidney and improve hemorheology indexes, which has a certain controlling effect on hematuria and proteinuria. In clinical verification, the drug has the advantages of fast therapeutic effect, good efficacy and small side effect.

The invention relates to an application of adriamycin and adenine jointly used in preparing animal models used for screening medicine for treating a CKD. According to the invention, the application dose of adriamycin is 2.5-10 mg/Kg each time, and the application dose of adenine is 200 mg/Kg every day. The animal model more accords with the occurrence and development process of the human CKD, experimental results prompt that the model making time can be shortened when the two kinds of medicine are applied jointly, and kidney injury is more serious at the same time point.

The invention relates to a beta-carboline compound and a synthesizing method and application thereof, and belongs to the technical field of medicines. The structure of the compound is shown in a formula I. Being proved by preliminary experiment, the beta-carboline compound has the advantages that the activity of resisting renal fibrosis in vitro is obvious, and the good potential medical value is realized; the beta-carboline compound can be applied to prepare various types of medicines for resisting renal fibrosis and chronic renal diseases. The formula I is shown in the description.

The present invention relates to a small molecule polypeptide TP-7 having a function of inhibiting a renal fibrosis-promoting function of extracellular matrix tenascin C (TNC) and particularly to a use of the small molecule polypeptide TP-7 in preparation of medicines for treating chronic kidney diseases (CKD). An amino acid sequence of the polypeptide TP-7 is shown in SEQ ID NO.1. In multiple mouse kidney fibrosis models, the TP-7 has a significant effect, can obviously restore renal functions, inhibits progress of renal fibrosis, is also free of obvious toxic and side effects, and thus can be prepared into pharmaceutical preparations for treating the chronic kidney diseases.

The invention relates to a beta-carboline compound as well as a synthesis method and application thereof, and belongs to the technical field of medicines. The structure of the compound is shown as a formula I. A primary experiment shows that the compound has remarkable in-vitro renal fibrosis resisting activity and has relatively good potential medical value; the beta-carboline compound can be used for preparing various renal-fibrosis-resisting and chronic-renal-disease-resisting medicines. (The formula I is shown in the description).